BioNotebook: BioMeter reads fewer, higher-value deals; trials progress, partnerships inked
This article was originally published in Scrip
Executive Summary
The fourth quarter of 2013 offered a mixed bag for biotechnology licensing deals; there were fewer transactions, but with much higher upfront payments than in previous quarters, according to law firm Morrison & Foerster's BioMeter report.